Product Description
Genervon was developing gm-604, an intravenous IGF Binder GM604 is an endogenous human embryonic stage neural regulatory and signaling peptide that controls the development, monitoring and correction of the human nervous system for Amyotrophic Lateral Disease. (Sourced from: https://www.genervon.com/clinical-trials)
Mechanisms of Action: IGF Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Genervon
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01854294 |
GALS | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2014-04-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/18/2019 |
News Article |
Insulin Like Growth Factor II Pipeline Review, H1 2019 Featuring 2 Companies & 8 Drug Profiles - ResearchAndMarkets.com |